Brainsway Ltd. (BWAY), a medical device company specializing in the treatment of mental health disorders, has seen its shares rise over 60% year-to-date as it gears up to capitalize on three critical catalysts. These include the FDA’s recent clearance of its Deep Transcranial Magnetic Stimulation (Deep TMS) as an adjunct treatment for adolescent Major Depressive Disorder (MDD), increased insurance coverage benefiting 57 million people, and promising one-year data from its SWIFT accelerated protocol. The company recently reported a revenue increase of 35% to $15.5 million, and net income surpassing $2.3 million, driven by a record 117 shipped Deep TMS systems, which brings their installed base to approximately 1,820 systems.
Analyst coverage for BRAINWAY remains sparse, but forecasts have shown significant upward revisions: current quarter estimates are up 43%, while next year’s earnings are projected to increase by more than 63%. With an estimated 31.2% revenue growth for this year, investors are keen on its trajectory. Notably, Brainsway’s expanded reimbursement policies and technical setup position the stock favorably for future growth, despite inherent risks as a smaller medical device firm.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
